PhaseBio Pharmaceuticals, Inc. PHAS
0.07 0.00 (+0.00%)
At closeNov 2, 2022, 4:00 PM EDT
0.0665 Day range 0.092
52-week range unavailable
News
benzinga.com Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.
benzinga.com Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 85 stocks hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday, 125 stocks hit new 52-week lows.
benzinga.com Why Qualtrics International Shares Are Trading Sharply Higher; Here Are 23 Stocks Moving Premarket Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose 43% to $2.16 in pre-market trading. Astellas Pharma Inc. announced plans to invest a total of $50 million to acquire 15% of Taysha Gene…- benzinga.com Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) climbed 62.4% to close at $0.39. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation.
benzinga.com Why Vaxcyte Shares Are Trading Sharply Higher? Here Are 63 Stocks Moving In Monday's Mid-Day Session Gainers Vaxcyte, Inc. (NASDAQ: PCVX) shares jumped 65% to $33.96 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety,…- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 413 companies reached new 52-week lows.
businesswire.com PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel…
businesswire.com PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code MALVERN, Pa.
247wallst.com These Were The Five Best And Worst Performing Healthcare Stocks In September 2022 September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.- benzinga.com Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.
- benzinga.com Why Sunlight Financial Shares Are Trading Lower By 59%, Here Are 54 Stocks Moving In Thursday's Mid-Day Session Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares jumped 52% to $2.1325 after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 361 companies set new 52-week lows.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022 Upgrades
benzinga.com Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session Gainers
zacks.com PhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue Estimates PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -3.03% and 91.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the…
businesswire.com PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel…
businesswire.com PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
benzinga.com Alibaba, Zoom Video And 76 Biggest Movers From Yesterday Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.- benzinga.com Coinbase, Moderna And 56 Biggest Movers From Yesterday Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares climbed 75.2% to close at $2.19 after the company announced it has developed a non-invasive blood sensor designated to alert…
- benzinga.com 89 Biggest Movers From Friday Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 1214 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 216 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 123 stocks made new 52-week lows.
zacks.com PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
businesswire.com PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel…
businesswire.com PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel…- businesswire.com PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
businesswire.com PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel…
businesswire.com PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel…- benzinga.com 53 Biggest Movers From Yesterday Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 64.4% to close at $1.41 on Thursday. Ally Bridge Group reported a purchase of 21.176 million shares of MedAvail Holdings for an average…
businesswire.com PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel…
businesswire.com PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference
businesswire.com PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel…
businesswire.com PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
businesswire.com PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel…
businesswire.com PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #Bentracimab--PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights- benzinga.com 58 Biggest Movers From Yesterday Gainers
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 671 companies achieved new lows for the year.
businesswire.com PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel…- businesswire.com PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update
benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 505 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 313 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 95 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks
- benzinga.com 52 Weeks High And Low Article On Friday, 106 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 109 companies set new 52-week lows.
- benzinga.com 70 Biggest Movers From Yesterday
- benzinga.com 28 Stocks Moving in Thursday's Pre-Market Session Gainers